The GLP-1 Hormone: Biology, Drug Class, and Genetics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article lives in the PlexusDx Education Hub, where we work through GLP-1 biology, weight-management protocols, and the genetic factors that sit beneath every metabolic decision. Browse the full Peptides & GLP-1 library.

Before "GLP-1" became shorthand for a medication category, it was a hormone your intestine releases when you eat. Understanding that origin makes the drug class far easier to follow. This article covers what GLP-1 is as a hormone, how receptor agonists reproduce and extend its effects, which medications belong to the class, the safety profile they share, and the genetic variation that sits upstream of every decision.

What GLP-1 is as a hormone

Glucagon-like peptide-1 is an incretin hormone produced by enteroendocrine L-cells in the small intestine in response to food. It prompts glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and signals satiety in the hypothalamus. Native GLP-1 has a very short half-life measured in minutes because the enzyme DPP-4 degrades it rapidly in circulation.

How receptor agonists extend its action

GLP-1 receptor agonists are peptides, and in newer cases small molecules, that bind the GLP-1 receptor while resisting DPP-4 breakdown, stretching the half-life from minutes to hours or days. They deliver the physiological effects of the native hormone at a pharmacological level: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signaling. Tirzepatide additionally engages the GIP receptor, a second incretin mechanism.

Which medications belong to the class

FDA-approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (historically, since discontinued in the U.S.), and semaglutide (Ozempic, Wegovy, Rybelsus). The GIP/GLP-1 dual agonist is tirzepatide (Mounjaro, Zepbound). The investigational triple agonist retatrutide, targeting GLP-1, GIP, and glucagon, has Phase 3 data but is not FDA-approved and is not sold by PlexusDx. Emerging oral non-peptide agonists such as orforglipron are in late-stage development.

What each is approved to do

Indications vary by compound and product: type 2 diabetes for most products, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for Ozempic, Trulicity, Victoza, and Rybelsus, and obstructive sleep apnea in adults with obesity for Zepbound as of December 2024. Certain products carry pediatric indications. Labeling governs what is prescribed for which use.

The shared safety profile

Every approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the boxed warning for thyroid C-cell tumors observed in rodent studies. Contraindications include a personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. The most common side effects are gastrointestinal, strongest during dose escalation, while serious reported events include pancreatitis, gallbladder disease, and acute kidney injury with dehydration.

The genetic variable in the pathway

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1 signaling, appetite regulation, and energy balance. They are pathway-level markers describing the biological terrain the class operates on rather than predictors of any single compound's effect. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, offered as educational context and and it does not tell you which medication or dose to choose. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Why the hormone framing matters

Starting from the hormone rather than the brand names makes the whole category coherent. Once you see that the medications exist to reproduce and prolong a natural signal the gut already sends, the differences between compounds become easier to place: some extend the half-life, some add a second receptor, some are still investigational. That framing also clarifies why side effects and warnings are shared across the class, since they stem from amplifying the same underlying biology.

From biology to a provider conversation

Understanding the hormone is a foundation, not a substitute for clinical guidance. If you are exploring whether any compound in this class fits your situation, bring your health history, current medications, and specific goals to a provider who can weigh the approved indications against your circumstances. Ask how the mechanism relates to what you are trying to achieve and how any plan would be monitored. Knowing your own metabolic terrain alongside the biology of the pathway is what turns general education into a personalized, well-grounded discussion.

Frequently Asked Questions

What is a GLP-1 receptor agonist?

It is a peptide, or an emerging small molecule, that binds the GLP-1 receptor and resists rapid degradation. It stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety. Approved examples include semaglutide, tirzepatide as a GIP/GLP-1 dual agonist, liraglutide, and dulaglutide.

How do dual agonists differ from single agonists?

Single agonists engage only the GLP-1 receptor. The dual agonist tirzepatide also engages the GIP receptor, adding a second incretin mechanism. Trial data from programs such as SURPASS and SURMOUNT suggest the dual-receptor approach may produce larger mean effects in some populations.

What does the genetic test measure?

It reports pathway-level variants in genes including FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology. It does not predict response to any specific compound and it does not tell you which medication or dose to choose. It provides upstream context for a conversation with your provider.

Related reading: GLP-1 Receptor Agonist, What Is GLP-1?, GLP-1 Drugs.

Keep reading across the PlexusDx Education Hub. Return to all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.